Aura Biosciences (NASDAQ:AURA – Get Rating) and Scholar Rock (NASDAQ:SRRK – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.
Profitability
This table compares Aura Biosciences and Scholar Rock’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aura Biosciences | N/A | -40.25% | -36.04% |
| Scholar Rock | N/A | -51.03% | -37.40% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for Aura Biosciences and Scholar Rock, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aura Biosciences | 0 | 0 | 1 | 0 | 3.00 |
| Scholar Rock | 0 | 0 | 5 | 0 | 3.00 |
Insider and Institutional Ownership
55.6% of Aura Biosciences shares are owned by institutional investors. Comparatively, 91.6% of Scholar Rock shares are owned by institutional investors. 5.0% of Aura Biosciences shares are owned by insiders. Comparatively, 2.1% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Aura Biosciences and Scholar Rock’s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aura Biosciences | N/A | N/A | -$58.76 million | ($1.96) | -4.34 |
| Scholar Rock | $33.19 million | 11.98 | -$134.50 million | ($2.28) | -3.36 |
Aura Biosciences has higher earnings, but lower revenue than Scholar Rock. Aura Biosciences is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Aura Biosciences has a beta of 0.07, suggesting that its stock price is 93% less volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.
Summary
Scholar Rock beats Aura Biosciences on 6 of the 11 factors compared between the two stocks.
About Aura Biosciences
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
About Scholar Rock
Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The firm offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
